• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

Hypertrophic cardiomyopathy (HCM) is a relatively common often inherited global heart
disease, with complex phenotypic and genetic expression and natural history, affecting both …

The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …

Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline
provides recommendations and algorithms for clinicians to diagnose and manage …

or therapeutic medical strategies. However, the ESC Guidelines do not override in any way
whatsoever the individual responsibility of health professionals to make appropriate and …

Making a firm diagnosis of chronic heart failure with preserved ejection fraction (HFpEF)
remains a challenge. We recommend a new stepwise diagnostic process, the 'HFA–PEFF …

Hypertrophic Cardiomyopathy HCM is the most common genetic disorder of the heart, with 1
case per 200 to 500 persons, and often remains clinically silent. HCM is the most common …

Prompt coronary catheterization and revascularization have markedly improved the
outcomes of myocardial infarction, but have also resulted in a growing number of surviving …

Cardiomyopathies are a heterogeneous group of heart muscle diseases and an important
cause of heart failure (HF). Current knowledge on incidence, pathophysiology and natural …